Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL9528444 | 0.79 | — | — | |
| Ether SCHEMBL2799096 | 0.78 | ALDH1A1 (0.44) | GAAALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL27442779 | 0.78 | GAA (0.44) | GAAALDH1A1LMNAHSD17B10TDP1 | |
| Ethoxycarbonyl Group SCHEMBL8821576 | 0.78 | ALDH1A1 (0.50) | GAAALDH1A1LMNAHSD17B10TDP1 | |
| Formic Acid SCHEMBL28097489 | 0.77 | GAA (0.42) | GAAALDH1A1TDP1CTSKDGAT1 | |
| Alcohol SCHEMBL21899723 | 0.77 | GAA (0.48) | GAAALDH1A1LMNAHSD17B10TDP1 | |
| Ethoxycarbonyl Group SCHEMBL4631753 | 0.77 | — | — | |
| Formic Acid SCHEMBL31505476 | 0.77 | GAA (0.42) | GAAALDH1A1TDP1CTSKDGAT1 | |
| SCHEMBL26684 | 0.76 | — | — | |
| SCHEMBL28745990 | 0.76 | GAA (0.50) | GAAALDH1A1LMNAHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737273-B2 | Process for acyclic phosphonate nucleotide analogs | HETERO DRUGS LIMITED (IN) | 2010-06-15 | — | — | US | claimed |
| US-20090012292-A1 | NOVEL PROCESS FOR ACYCLIC PHOSPHONATE NUCLEOTIDE ANALOGS | HETERO DRUGS LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| EP-1907391-A1 | NOVEL PROCESS FOR ACYCLIC PHOSPHONATE NUCLEOTIDE ANALOGS | Hetero Drugs Limited (IN) | 2008-04-09 | — | — | EP | claimed |
| WO-2007013085-A1 | NOVEL PROCESS FOR ACYCLIC PHOSPHONATE NUCLEOTIDE ANALOGS | HETERO DRUGS LIMITED (IN) | 2007-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012292-A1 | NOVEL PROCESS FOR ACYCLIC PHOSPHONATE NUCLEOTIDE ANALOGS | TYMP, DUT, DPYD | GAA 1772/4885ALDH1A1 2409/4885LMNA 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.